# Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy

> **NCT01805830** · PHASE3 · COMPLETED · sponsor: **Handok Inc.** · enrollment: 189 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** MP513
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01805830
- **Lead sponsor:** Handok Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-09
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2015-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01805830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01805830, "Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01805830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*